文献速递系统性红斑狼疮

尿液蛋白质组学与肾脏单细胞转录组学提示白细胞介素-16参与狼疮性肾炎

Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.
PubMed 文献 · Arthritis Rheumatol · 2022-04-16

研究对30例狼疮性肾炎患者在肾活检时及3、6、12个月时定量尿液中的1000种蛋白质,并结合肾脏活检单细胞转录组学分析。发现237种尿液生物标志物与狼疮性肾炎相关,尿白细胞介素-16随治疗反应而下降,单细胞RNA测序显示IL16是狼疮肾炎肾脏中大多数浸润免疫细胞表达第二多的细胞因子。

要点

  • 尿液蛋白质组学可无创监测狼疮性肾炎肾脏内活跃的生物学通路。
  • 尿白细胞介素-16、CD163和转化生长因子β反映肾脏内肾炎活动度。
  • 单细胞RNA测序显示IL16是狼疮肾炎肾脏浸润免疫细胞表达第二多的细胞因子。

核心结论

  • 尿液蛋白质组学可能深刻改变狼疮性肾炎的诊断和管理方式,实现无创监测肾脏内活跃的生物学通路。
  • 这些发现提示白细胞介素-16参与狼疮性肾炎的发病机制,将其定位为潜在可治疗靶点和生物标志物。

研究设计与样本

  • 研究对30例狼疮性肾炎患者在诊断性肾活检时及之后3、6、12个月定量尿液中的1000种蛋白质。
  • 将尿液蛋白质组中检测到的蛋白质和分子通路与基线临床特征及纵向轨迹进行分析。
  • 利用狼疮性肾炎患者肾活检切片的单细胞转录组学评估候选生物标志物的肾内表达。

主要发现

  • 分析揭示趋化性、中性粒细胞激活、血小板脱颗粒和细胞外基质组织等多个生物学通路可在尿液中无创定量和监测。
  • 与无系统性红斑狼疮的对照相比,鉴定出237种与狼疮性肾炎相关的尿液生物标志物。
  • 白细胞介素-16、CD163和转化生长因子β反映肾脏内肾炎活动度。
  • 对治疗的反应与尿白细胞介素-16下降相平行,白细胞介素-16是具有促炎和趋化特性的CD4配体。
  • 单细胞RNA测序独立显示IL16是狼疮性肾炎肾脏中大多数浸润免疫细胞表达第二多的细胞因子,产白细胞介素-16的细胞存在于肾脏损伤的关键部位。

关键数值与推荐

  • 在30例狼疮性肾炎患者中定量尿液1000种蛋白质,鉴定出237种与狼疮性肾炎相关的尿液生物标志物(对比无系统性红斑狼疮的对照)。
  • 尿白细胞介素-16、CD163和转化生长因子β反映肾脏内肾炎活动度,治疗反应与尿白细胞介素-16下降相平行。
  • 单细胞RNA测序显示IL16是狼疮性肾炎肾脏中大多数浸润免疫细胞表达第二多的细胞因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Current lupus nephritis (LN) treatments are effective in only 30% of patients, emphasizing the need for novel therapeutic strategies. We undertook this study to develop mechanistic hypotheses and explore novel biomarkers by analyzing the longitudinal urinary proteomic profiles in LN patients undergoing treatment. METHODS: We quantified 1,000 urinary proteins in 30 patients with LN at the time of the diagnostic renal biopsy and after 3, 6, and 12 months. The proteins and molecular pathways detected in the urine proteome were then analyzed with respect to baseline clinical features and longitudinal trajectories. The intrarenal expression of candidate biomarkers was evaluated using single-cell transcriptomics of renal biopsy sections from LN patients. RESULTS: Our analysis revealed multiple biologic pathways, including chemotaxis, neutrophil activation, platelet degranulation, and extracellular matrix organization, which could be noninvasively quantified and monitored in the urine. We identified 237 urinary biomarkers associated with LN, as compared to controls without systemic lupus erythematosus. Interleukin-16 (IL-16), CD163, and transforming growth factor β mirrored intrarenal nephritis activity. Response to treatment was paralleled by a reduction in urinary IL-16, a CD4 ligand with proinflammatory and chemotactic properties. Single-cell RNA sequencing independently demonstrated that IL16 is the second most expressed cytokine by most infiltrating immune cells in LN kidneys. IL-16-producing cells were found at key sites of kidney injury. CONCLUSION: Urine proteomics may profoundly change the diagnosis and management of LN by noninvasively monitoring active intrarenal biologic pathways. These findings implicate IL-16 in LN pathogenesis, designating it as a potentially treatable target and biomarker.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fava A, Rao DA, Mohan C, et al. Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. Arthritis Rheumatol. 2022. PMID: 34783463. doi:10.1002/art.42023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。